Compare TRIB & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | SNTI |
|---|---|---|
| Founded | 1992 | 2016 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 53.6M |
| IPO Year | N/A | N/A |
| Metric | TRIB | SNTI |
|---|---|---|
| Price | $1.06 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 83.5K | ★ 4.1M |
| Earning Date | 03-23-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,555,000.00 | N/A |
| Revenue This Year | $13.51 | N/A |
| Revenue Next Year | $13.14 | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.31 | N/A |
| 52 Week Low | $0.48 | $1.26 |
| 52 Week High | $3.44 | $5.96 |
| Indicator | TRIB | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 34.89 |
| Support Level | $1.04 | $1.34 |
| Resistance Level | $1.22 | $2.88 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 59.97 | 2.48 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.